Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-19-019424
Filing Date
2019-05-15
Accepted
2019-05-15 16:27:56
Documents
56
Period of Report
2019-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q achv-10q_20190331.htm 10-Q 1544597
2 EX-31.1 achv-ex311_7.htm EX-31.1 9047
3 EX-31.2 achv-ex312_8.htm EX-31.2 9083
4 EX-32.1 achv-ex321_6.htm EX-32.1 4830
5 EX-32.2 achv-ex322_10.htm EX-32.2 4857
  Complete submission text file 0001564590-19-019424.txt   5534247

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT achv-20190331.xml EX-101.INS 1090829
7 XBRL TAXONOMY EXTENSION SCHEMA achv-20190331.xsd EX-101.SCH 46585
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE achv-20190331_cal.xml EX-101.CAL 44077
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE achv-20190331_def.xml EX-101.DEF 162561
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE achv-20190331_lab.xml EX-101.LAB 368615
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE achv-20190331_pre.xml EX-101.PRE 281202
Mailing Address 520 PIKE STREET SUITE 2250 SEATTLE WA 98101
Business Address 520 PIKE STREET SUITE 2250 SEATTLE WA 98101 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Filer) CIK: 0000949858 (see all company filings)

IRS No.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 033-80623 | Film No.: 19828672
SIC: 2835 In Vitro & In Vivo Diagnostic Substances